Curis Inc
CUS0
Company Profile
Business description
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Contact
128 Spring Street
Building C - Suite 500
LexingtonMA02421
USAT: +1 617 503-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
33
Stocks News & Analysis
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
stocks
Anthropic’s Claude code security release is not bad news for cyber stocks
We believe cyber vendors will be able to adopt LLM’s for their benefit.
stocks
Earnings losers: TWE, GMG, SUN and more fall on weaker profits
Where companies fell short of market expectations in the third week of earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,244.30 | 16.50 | -0.18% |
| CAC 40 | 8,519.21 | 22.04 | 0.26% |
| DAX 40 | 25,021.65 | 29.68 | 0.12% |
| Dow JONES (US) | 49,139.51 | 335.45 | 0.69% |
| FTSE 100 | 10,680.59 | 4.15 | -0.04% |
| HKSE | 26,590.32 | 491.59 | -1.82% |
| NASDAQ | 22,847.83 | 220.56 | 0.97% |
| Nikkei 225 | 57,321.09 | 495.39 | 0.87% |
| NZX 50 Index | 13,532.31 | 111.88 | 0.83% |
| S&P 500 | 6,880.82 | 43.07 | 0.63% |
| S&P/ASX 200 | 9,022.30 | 12.10 | -0.13% |
| SSE Composite Index | 4,117.41 | 35.34 | 0.87% |